Coadjuvants in the diabetic complications: Nutraceuticals and drugs with pleiotropic effects

International Journal of Molecular Sciences

Volumn 17, Issue 8, 2016, Pages

  Pereira, Thiago Melo Costa ^a,b   Pimenta, Fabio Silva ^a,c   Porto, Marcella Lima ^b   Baldo, Marcelo Perim ^d   Campagnaro, Bianca Prandi ^a   Gava, Agata Lages ^e,f   Meyrelles, Silvana Santos ^e   Vasquez, Elisardo Corral ^a,e  

^a UNIVERSIDADE VILA VELHA   (Brazil)

^b Federal Institute of Education   (Brazil)

^c Children State Hospital   (Brazil)

^d State University at Montes Claros (UNIMONTES)   (Brazil)

^e FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

Antioxidants; Diabetes; Kefir; Phosphodiesterase inhibitors; Polyphenols; Probiotic; Quercetin; Resveratrol; Sildenafil; Silymarin

Indexed keywords

KEFIR; NUTRACEUTICAL; PHOSPHODIESTERASE V INHIBITOR; POLYPHENOL; PROBIOTIC AGENT; QUERCETIN; RESVERATROL; ANTIDIABETIC AGENT; BIOLOGICAL PRODUCT; PHARMACEUTICAL VEHICLES AND ADDITIVES;

DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; LACTOBACILLUS; LACTOCOCCUS; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; REVIEW; STREPTOCOCCUS; COMPLICATION; DIABETES COMPLICATIONS; DIETARY SUPPLEMENT;

ADJUVANTS, PHARMACEUTIC; BIOLOGICAL PRODUCTS; DIABETES COMPLICATIONS; DIETARY SUPPLEMENTS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS;

EID: 84981187928     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17081273     Document Type: Review

References (230)

1. Garcia-Perez, L.E.; Alvarez, M.; Dilla, T.; Gil-Guillen, V.; Orozco-Beltran, D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013, 4, 175-194.
2. Cheung, B.M.; Ong, K.L.; Cherny, S.S.; Sham, P.C.; Tso, A.W.; Lam, K.S. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am. J. Med. 2009, 122, 443-453.
3. Gu, K.; Cowie, C.C.; Harris, M.I. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 1998, 21, 1138-1145.
4. Potenza, M.A.; Gagliardi, S.; Nacci, C.; Carratu, M.R.; Montagnani, M. Endothelial dysfunction in diabetes: From mechanisms to therapeutic targets. Curr. Med. Chem. 2009, 16, 94-112.
5. Santi, D.; Giannetta, E.; Isidori, A.M.; Vitale, C.; Aversa, A.; Simoni, M. Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: A meta-analysis. Eur. J. Endocrinol. 2015, 172, R103-R114.
6. Ong, K.L.; Cheung, B.M.; Wong, L.Y.; Wat, N.M.; Tan, K.C.; Lam, K.S. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann. Epidemiol. 2008, 18, 222-229.
7. Wegman, M.P.; Guo, M.H.; Bennion, D.M.; Shankar, M.N.; Chrzanowski, S.M.; Goldberg, L.A.; Xu, J.; Williams, T.A.; Lu, X.; Hsu, S.I. et al. Practicality of intermittent fasting in humans and its effect on oxidative stress and genes related to aging and metabolism. Rejuvenation Res. 2015, 18, 162-172.
8. Wang, Y. Molecular Links between Caloric Restriction and Sir2/SIRT1 Activation. Diabetes Metab. J. 2014, 38, 321-329.
9. Kuecker, C.M.; Vivian, E.M. Patient considerations in type 2 diabetes—Role of combination dapagliflozin-metformin XR. Diabetes Metab. Syndr. Obes. 2016, 9, 25-35.
10. Sharma, B.R.; Kim, H.J.; Rhyu, D.Y. Caulerpa lentillifera extract ameliorates insulin resistance and regulates glucose metabolism in C57BL/KsJ-db/db mice via PI3K/AKT signaling pathway in myocytes. J. Transl. Med. 2015, 13, 62.
11. Shera, A.S.; Jawad, F.; Maqsood, A.; Jamal, S.; Azfar, M.; Ahmed, U. Prevalence of chronic complications and associated factors in type 2 diabetes. J. Pak. Med. Assoc. 2004, 54, 54-59.
12. Siddiqui, F.J.; Avan, B.I.; Mahmud, S.; Nanan, D.J.; Jabbar, A.; Assam, P.N. Uncontrolled diabetes mellitus: Prevalence and risk factors among people with type 2 diabetes mellitus in an Urban District of Karachi, Pakistan. Diabetes Res. Clin. Pract. 2015, 107, 148-156.
13. Hamwi, G.J.; Garcia, O.; Kruger, F.A.; Gwinup, G.; Cornwell, D.G. Hyperlipidemia in uncontrolled diabetes. Metabolism 1962, 11, 850-862.
14. Moinat, P.; Nichols, N.; Tuller, E.F. Changes in serum proteins and polysaccharides in rats with uncontrolled diabetes. Diabetes 1956, 5, 468-474.
15. Litchfield, J.A. Biochemical changes in skeletal muscle in patients with uncontrolled diabetes mellitus. Diabetes 1959, 8, 257-260.
16. Afsharian, S.; Akbarpour, S.; Abdi, H.; Sheikholeslami, F.; Moeini, A.S.; Khalili, D.; Momenan, A.A.; Azizi, F.; Hadaegh, F. Risk factors for cardiovascular disease and mortality events in adults with type 2 diabetes: A 10 year follow-up: Tehran lipid and glucose study. Diabetes Metab. Res. Rev. 2016.
17. Mulnier, H.E.; Seaman, H.E.; Raleigh, V.S.; Soedamah-Muthu, S.S.; Colhoun, H.M.; Lawrenson, R.A.; de Vries, C.S. Risk of myocardial infarction in men and women with type 2 diabetes in the UK: A cohort study using the General Practice Research Database. Diabetologia 2008, 51, 1639-1645.
18. An, Y.; Zhang, P.; Wang, J.; Gong, Q.; Gregg, E.W.; Yang, W.; Li, H.; Zhang, B.; Shuai, Y.; Chen, Y. et al. Cardiovascular and all-cause mortality over a 23-year period among chinese with newly diagnosed diabetes in the Da Qing IGT and Diabetes Study. Diabetes Care 2015, 38, 1365-1371.
19. Peters, S.A.; Huxley, R.R.; Woodward, M. Diabetes as a risk factor for stroke in women compared with men: A systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet 2014, 383, 1973-1980.
20. Lee, M.; Saver, J.L.; Hong, K.S.; Song, S.; Chang, K.H.; Ovbiagele, B. Effect of pre-diabetes on future risk of stroke: Meta-analysis. BMJ 2012, 344.
21. Collins, A.J.; Foley, R.N.; Herzog, C.; Chavers, B.; Gilbertson, D.; Ishani, A.; Kasiske, B.; Liu, J.; Mau, L.W.; McBean, M. et al. US renal data system 2010 annual data report. Am. J. Kidney Dis. 2011, 57, e1-e526.
22. Radbill, B.; Murphy, B.; LeRoith, D. Rationale and strategies for early detection and management of diabetic kidney disease. Mayo Clin. Proc. 2008, 83, 1373-1381.
23. de Boer, I.H.; Rue, T.C.; Hall, Y.N.; Heagerty, P.J.; Weiss, N.S.; Himmelfarb, J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011, 305, 2532-2539.
24. Salinero-Fort, M.Á.; San Andrés-Rebollo, F.J.; de Burgos-Lunar, C.; Abánades-Herranz, J.C.; Carrillo-de-Santa-Pau, E.; Chico-Moraleja, R.M.; Jiménez-García, R.; López-de-Andrés, A.; Gómez-Campelo, P. Cardiovascular and all-cause mortality in patients with type 2 diabetes mellitus in the MADIABETES Cohort Study: Association with chronic kidney disease. J. Diabetes Complic. 2016, 30, 227-236.
25. Brownlee, M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005, 54, 1615-1625.
26. Kitabchi, A.E.; Umpierrez, G.E.; Miles, J.M.; Fisher, J.N. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009, 32, 1335-1343.
27. Kitabchi, A.E.; Nyenwe, E.A. Hyperglycemic crises in diabetes mellitus: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Endocrinol. Metab. Clin. N. Am. 2006, 35, 725-751.
28. Davis, S.N.; Umpierrez, G.E. Diabetic ketoacidosis in type 2 diabetes mellitus-pathophysiology and clinical presentation. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3, 730-731.
29. Lewko, B.; Stepinski, J. Hyperglycemia and mechanical stress: Targeting the renal podocyte. J. Cell. Physiol. 2009, 221, 288-295.
30. Di Mario, U.; Pugliese, G. 15th Golgi lecture: From hyperglycaemia to the dysregulation of vascular remodelling in diabetes. Diabetologia 2001, 44, 674-692.
31. Beisswenger, P.J.; Howell, S.K.; Nelson, R.G.; Mauer, M.; Szwergold, B.S. -Oxoaldehyde metabolism and diabetic complications. Biochem. Soc. Trans. 2003, 31, 1358-1363.
32. Nishikawa, T.; Edelstein, D.; Du, X.L.; Yamagishi, S.; Matsumura, T.; Kaneda, Y.; Yorek, M.A.; Beebe, D.; Oates, P.J.; Hammes, H.P. et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404, 787-790.
33. Lee, H.B.; Yu, M.R.; Yang, Y.; Jiang, Z.; Ha, H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14, S241-S245.
34. Dunlop, M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int. Suppl. 2000, 77, S3-S12.
35. Tomlinson, D.R.; Gardiner, N.J. Glucose neurotoxicity. Nat. Rev. Neurosci. 2008, 9, 36-45.
36. Luo, X.; Wu, J.; Jing, S.; Yan, L.J. Hyperglycemic stress and carbon stress in diabetic glucotoxicity. Aging Dis. 2016, 7, 90-110.
37. Ying, W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: Regulation and biological consequences. Antioxid. Redox Signal. 2008, 10, 179-206.
38. Dolle, C.; Rack, J.G.; Ziegler, M. NAD and ADP-ribose metabolism in mitochondria. FEBS J. 2013, 280, 3530-3541.
39. Du, X.L.; Edelstein, D.; Rossetti, L.; Fantus, I.G.; Goldberg, H.; Ziyadeh, F.; Wu, J.; Brownlee, M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl. Acad. Sci. USA 2000, 97, 12222-12226.
40. Porto, M.L.; Rodrigues, B.P.; Menezes, T.N.; Ceschim, S.L.; Casarini, D.E.; Gava, A.L.; Pereira, T.M.; Vasquez, E.C.; Campagnaro, B.P.; Meyrelles, S.S. Reactive oxygen species contribute to dysfunction of bone marrow hematopoietic stem cells in aged C57BL/6 J mice. J. Biomed. Sci. 2015, 22, 97.
41. Nakagami, H.; Morishita, R.; Yamamoto, K.; Yoshimura, S.I.; Taniyama, Y.; Aoki, M.; Matsubara, H.; Kim, S.; Kaneda, Y.; Ogihara, T. Phosphorylation of p38 mitogen-activated protein kinase downstream of bax-caspase-3 pathway leads to cell death induced by high D-glucose in human endothelial cells. Diabetes 2001, 50, 1472-1481.
42. Nakagami, H.; Kaneda, Y.; Ogihara, T.; Morishita, R. Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. Curr. Diabetes Rev. 2005, 1, 59-63.
43. Wei, W.; Liu, Q.; Tan, Y.; Liu, L.; Li, X.; Cai, L. Oxidative stress, diabetes, and diabetic complications. Hemoglobin 2009, 33, 370-377.
44. Domingueti, C.P.; Dusse, L.M.; Carvalho, M.D.; de Sousa, L.P.; Gomes, K.B.; Fernandes, A.P. Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J. Diabetes Complic. 2016, 30, 738-745.
45. Gomes, I.B.; Porto, M.L.; Santos, M.C.; Campagnaro, B.P.; Pereira, T.M.; Meyrelles, S.S.; Vasquez, E.C. Renoprotective, anti-oxidative and anti-apoptotic effects of oral low-dose quercetin in the C57BL/6J model of diabetic nephropathy. Lipids Health Dis. 2014, 6, 184.
46. Gomes, I.B.; Porto, M.L.; Santos, M.C.; Campagnaro, B.P.; Gava, A.L.; Meyrelles, S.S.; Pereira, T.M.; Vasquez, E.C. The protective effects of oral low-dose quercetin on diabetic nephropathy in hypercholesterolemic mice. Front. Physiol. 2015, 6, 247.
47. Holmström, K.M.; Finkel, T. Cellular mechanisms and physiological consequences of redox-dependent signaling. Nat. Rev. Mol. Cell Biol. 2014, 15, 411-421.
48. Kayama, Y.; Raaz, U.; Jagger, A.; Adam, M.; Schellinger, I.N.; Sakamoto, M.; Suzuki, H.; Toyama, K.; Spin, J.M.; Tsao, P.S. Diabetic cardiovascular disease induced by oxidative stress. Int. J. Mol. Sci. 2015, 16, 25234-25263.
49. Münzel, T.; Gori, T.; Bruno, R.M.; Taddei, S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur. Heart J. 2010, 31, 2741-2748.
50. Ceriello, A.; Testa, R.; Genovese, S. Clinical implications of oxidative stress and potential role of natural antioxidants in diabetic vascular complications. Nutr. Metab. Cardiovasc. Dis. 2016, 26, 285-292.
51. Ide, T.; Tsutsui, H.; Kinugawa, S.; Utsumi, H.; Kang, D.; Hattori, N.; Uchida, K.; Arimura, K.; Egashira, K.; Takeshita, A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ. Res 1999, 85, 357-363.
52. Selemidis, S.; Sobey, C.G.; Wingler, K.; Schmidt, H.H.; Drummond, G.R. NADPH oxidases in the vasculature: Molecular features, roles in disease and pharmacological inhibition. Pharmacol. Ther. 2008, 120, 254-291.
53. Zhou, G.; Li, X.; Hein, D.W.; Xiang, X.; Marshall, J.P.; Prabhu, S.D.; Cai, L. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J. Am. Coll. Cardiol. 2008, 52, 655-666.
54. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414, 813-820.
55. Tan, S.M.; de Haan, J.B. Combating oxidative stress in diabetic complications with Nrf2 activators: How much is too much? Redox Rep. 2014, 19, 107-117.
56. Xu, X.; Luo, P.; Wang, Y.; Cui, Y.; Miao, L. Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) is a novel therapeutic target for diabetic complications. J. Int. Med. Res. 2013, 41, 13-19.
57. Murali, R.; Karthikeyan, A.; Saravanan, R. Protective effects of D-limonene on lipid peroxidation and antioxidant enzymes in streptozotocin-induced diabetic rats. Basic Clin. Pharmacol. Toxicol. 2013, 112, 175-181.
58. Ghattas, M.H.; Abo-Elmatty, D.M. Association of polymorphic markers of the catalase and superoxide dismutase genes with type 2 diabetes mellitus. DNA Cell Biol. 2012, 31, 1598-1603.
59. Batinic-Haberle, I.; Reboucas, J.S.; Spasojevic, I. Superoxide dismutase mimics: Chemistry, pharmacology, and therapeutic potential. Antioxid. Redox Signal. 2010, 13, 877-918.
60. Soto-Urquieta, M.G.; López-Briones, S.; Pérez-Vázquez, V.; Saavedra-Molina, A.; González-Hernández, G.A.; Ramírez-Emiliano, J. Curcumin restores mitochondrial functions and decreases lipid peroxidation in liver and kidneys of diabetic db/db mice. Biol. Res. 2014, 47,74.
61. Pitocco, D.; Tesauro, M.; Alessandro, R.; Ghirlanda, G.; Cardillo, C. Oxidative stress in diabetes: Implications for vascular and other complications. Int. J. Mol. Sci. 2013.
62. Liu, X.; Gan, W.; Zou, Y.; Yang, B.; Su, Z.; Deng, J.; Wang, L.; Cai, J. Elevated levels of urinary markers of oxidative DNA and RNA damage in type 2 diabetes with complications. Oxid. Med. Cell. Longev. 2016, 2016, 4323198.
63. Palem, S.P.; Abraham, P. A study on the level of oxidative stress and inflammatory markers in type 2 diabetes mellitus patients with different treatment modalities. J. Clin. Diagn. Res. 2015.
64. Araki, E.; Nishikawa, T. Oxidative stress: A cause and therapeutic target of diabetic complications. J. Diabetes Investig. 2010, 1, 90-96.
65. Zatalia, S.R.; Sanusi, H. The role of antioxidants in the pathophysiology, complications, and management of diabetes mellitus. Acta Med. Indones 2013, 45, 141-147.
66. Su, H.C.; Hung, L.M.; Chen, J.K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 2006, 290, E1339-E1346.
67. Zhang, Z.; Li, Y.; Li, Y. Grape seed proanthocyanidin extracts prevent hyperglycemia-induced monocyte adhesion to aortic endothelial cells and ameliorates vascular inflammation in high-carbohydrate/high-fat diet and streptozotocin-induced diabetic rats. Int. J. Food Sci. Nutr. 2015, 67, 524-534.
68. D’Andrea, G. Quercetin: A flavonol with multifaceted therapeutic applications? Fitoterapia 2015, 106, 256-271.
69. Liu, J.Y.; Chen, X.X.; Tang, S.C.; Sze, S.C.; Feng, Y.; Lee, K.F.; Zhang, K.Y. Chinese medicines in the treatment of experimental diabetic nephropathy. Chin. Med. 2016, 11, 6.
70. Okamoto, T. Safety of quercetin for clinical application (Review). Int. J. Mol. Med. 2005, 16, 275-278.
71. Varma, S.D.; Mikuni, I.; Kinoshita, J.H. Flavonoids as inhibitors of lens aldose reductase. Science 1975, 188, 1215-1216.
72. Alam, M.M.; Meerza, D.; Naseem, I. Protective effect of quercetin on hyperglycemia, oxidative stress and DNA damage in alloxan induced type 2 diabetic mice. Life Sci. 2014, 109, 8-14.
73. Xu, M.; Hu, J.; Zhao, W.; Gao, X.; Jiang, C.; Liu, K.; Liu, B.; Huang, F. Quercetin differently regulates insulin-mediated glucose transporter 4 translocation under basal and inflammatory conditions in adipocytes. Mol. Nutr. Food Res. 2014, 58, 931-941.
74. Henagan, T.M.; Lenard, N.R.; Gettys, T.W.; Stewart, L.K. Dietary quercetin supplementation in mice increases skeletal muscle PGC1 expression, improves mitochondrial function and attenuates insulin resistance in a time-specific manner. PLoS ONE 2014, 9, e89365.
75. Eid, H.M.; Nachar, A.; Thong, F.; Sweeney, G.; Haddad, P.S. The molecular basis of the antidiabetic action of quercetin in cultured skeletal muscle cells and hepatocytes. Pharmacogn. Mag. 2015, 11, 74-81.
76. Kim, J.H.; Kang, M.J.; Choi, H.N.; Jeong, S.M.; Lee, Y.M.; Kim, J.I. Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus. Nutr. Res. Pract. 2011, 5, 107-111.
77. Kwon, O.; Eck, P.; Chen, S.; Corpe, C.P.; Lee, J.H.; Kruhlak, M.; Levine, M. Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. FASEB J. 2007, 21, 366-377.
78. Mahesh, T.; Menon, V.P. Quercetin allievates oxidative stress in streptozotocin-induced diabetic rats. Phytother. Res. 2004, 18, 123-127.
79. Oršolić, N.; Gajski, G.; Garaj-Vrhovac, V.; Dikić, D.; Prskalo, Z.Š.; Sirovina, D. DNA-protective effects of quercetin or naringenin in alloxan-induced diabetic mice. Eur. J. Pharmacol. 2011, 656, 110-118.
80. Hollman, P.C.; van Trijp, J.M.; Buysman, M.N.; van der Gaag, M.S.; Mengelers, M.J.; de Vries, J.H.; Katan, M.B. Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett. 1997, 418, 152-156.
81. De Boer, V.C.; Dihal, A.A.; van der Woude, H.; Arts, I.C.; Wolffram, S.; Alink, G.M.; Rietjens, I.M.; Keijer, J.; Hollman, P.C. Tissue distribution of quercetin in rats and pigs. J. Nutr. 2005, 135, 1718-1725.
82. Bakhshaeshi, M.; Khaki, A.; Fathiazad, F.; Khaki, A.A.; Ghadamkheir, E. Anti-oxidative role of quercetin derived from Allium cepa on aldehyde oxidase (OX-LDL) and hepatocytes apoptosis in streptozotocin-induced diabetic rat. Asian Pac. J. Trop. Biomed. 2012, 2, 528-531.
83. Dodda, D.; Ciddi, V. Plants used in the management of diabetic complications. Indian J. Pharm. Sci. 2014, 76, 97-106.
84. Umathe, S.N.; Dixit, P.V.; Kumar, V.; Bansod, K.U.; Wanjari, M.M. Quercetin pretreatment increases the bioavailability of pioglitazone in rats: Involvement of CYP3A inhibition. Biochem. Pharmacol. 2008, 75, 1670-1676.
85. Sanders, R.A.; Rauscher, F.M.; Watkins, J.B. Effects of quercetin on antioxidant defense in streptozotocin-induced diabetic rats. J. Biochem. Mol. Toxicol. 2001, 15, 143-149.
86. Elbe, H.; Esrefoglu, M.; Vardi, N.; Taslidere, E.; Ozerol, E.; Tanbek, K. Melatonin, quercetin and resveratrol attenuates oxidative hepatocellular injury in streptozotocin-induced diabetic rats. Hum. Exp. Toxicol. 2015, 34, 859-868.
87. Ortega, R.; García, N. The flavonoid quercetin induces changes in mitochondrial permeability by inhibiting adenine nucleotide translocase. J. Bioenerg. Biomembr. 2009, 41, 41-47.
88. Sivitz, W.I.; Yorek, M.A. Mitochondrial dysfunction in diabetes: From molecular mechanisms to functional significance and therapeutic opportunities. Antioxid. Redox Signal. 2010, 12, 537-577.
89. Kowluru, R.A.; Mishra, M. Oxidative stress, mitochondrial damage and diabetic retinopathy. Biochim. Biophys. Acta 2015, 1852, 2474-2483.
90. Gonzalez Suarez, M.L.; Thomas, D.B.; Barisoni, L.; Fornoni, A. Diabetic nephropathy: Is it time yet for routine kidney biopsy? World J. Diabetes 2013, 4, 245-255.
91. Kushiyama, A.; Tanaka, K.; Hara, S.; Kawazu, S. Linking uric acid metabolism to diabetic complications. World J. Diabetes 2014, 5, 787-795.
92. Kumar, B.; Gupta, S.K.; Nag, T.C.; Srivastava, S.; Saxena, R.; Jha, K.A.; Srinivasan, B.P. Retinal neuroprotective effects of quercetin in streptozotocin-induced diabetic rats. Exp. Eye Res. 2014, 125, 193-202.
93. Mahmoud, M.F.; Hassan, N.A.; El Bassossy, H.M.; Fahmy, A. Quercetin protects against diabetes-induced exaggerated vasoconstriction in rats: Effect on low grade inflammation. PLoS ONE 2013, 8, e63784.
94. Zhang, W.; Wang, Y.; Yang, Z.; Qiu, J.; Ma, J.; Zhao, Z.; Bao, T. Antioxidant treatment with quercetin ameliorates erectile dysfunction in streptozotocin-induced diabetic rats. J. Biosci. Bioeng. 2011, 112, 215-218.
95. Anjaneyulu, M.; Chopra, K. Quercetin attenuates thermal hyperalgesia and cold allodynia in STZ-induced diabetic rats. Indian J. Exp. Biol. 2004, 42, 766-769.
96. Anjaneyulu, M.; Chopra, K. Quercetin, an anti-oxidant bioflavonoid, attenuates diabetic nephropathy in rats. Clin. Exp. Pharmacol. Physiol. 2004, 31, 244-248.
97. Chen, P.; Chen, J.; Zheng, Q.; Chen, W.; Wang, Y.; Xu, X. Pioglitazone, extract of compound Danshen dripping pill, and quercetin ameliorate diabetic nephropathy in diabetic rats. J. Endocrinol. Investig. 2013, 36, 422-427.
98. Wang, C.; Pan, Y.; Zhang, Q.Y.; Wang, F.M.; Kong, L.D. Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation. PLoS ONE 2012, 7, e38285.
99. Jeong, S.M.; Kang, M.J.; Choi, H.N.; Kim, J.H.; Kim, J.I. Quercetin ameliorates hyperglycemia and dyslipidemia and improves antioxidant status in type 2 diabetic db/db mice. Nutr. Res Pract. 2012, 6, 201-207.
100. Shi, Y.; Williamson, G. Quercetin lowers plasma uric acid in pre-hyperuricaemic males: A randomised, double-blinded, placebo-controlled, cross-over trial. Br. J. Nutr. 2016, 115, 800-806.
101. Zahedi, M.; Ghiasvand, R.; Feizi, A.; Asgari, G.; Darvish, L. Does quercetin improve cardiovascular risk factors and inflammatory biomarkers in women with type 2 diabetes: A double-blind randomized controlled clinical trial. Int. J. Prev. Med. 2013, 4, 777-785.
102. Brüll, V.; Burak, C.; Stoffel-Wagner, B.; Wolffram, S.; Nickenig, G.; Müller, C.; Langguth, P.; Alteheld, B.; Fimmers, R.; Naaf, S. et al. Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: A randomised double-blinded placebo-controlled cross-over trial. Br. J. Nutr. 2015, 114, 1263-1277.
103. Dower, J.I.; Geleijnse, J.M.; Gijsbers, L.; Zock, P.L.; Kromhout, D.; Hollman, P.C. Effects of the pure flavonoids epicatechin and quercetin on vascular function and cardiometabolic health: A randomized, double-blind, placebo-controlled, crossover trial. Am. J. Clin. Nutr. 2015, 101, 914-921.
104. Renaud, S.; de Lorgeril, M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992, 339, 1523-1526.
105. Nishizuka, T.; Fujita, Y.; Sato, Y.; Nakano, A.; Kakino, A.; Ohshima, S.; Kanda, T.; Yoshimoto, R.; Sawamura, T. Procyanidins are potent inhibitors of LOX-1: A new player in the French Paradox. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2011, 87, 104-113.
106. Bonnefont-Rousselot, D. Resveratrol and cardiovascular diseases. Nutrients 2016, 8, E250.
107. Lin, Y.L.; Chang, H.C.; Chen, T.L.; Chang, J.H.; Chiu, W.T.; Lin, J.W.; Chen, R.M. Resveratrol protects against oxidized LDL-induced breakage of the blood-brain barrier by lessening disruption of tight junctions and apoptotic insults to mouse cerebrovascular endothelial cells. J. Nutr. 2010, 140, 2187-2192.
108. Posadino, A.M.; Cossu, A.; Giordo, R.; Zinellu, A.; Sotgia, S.; Vardeu, A.; Hoa, P.T.; Nguyen le, H.V.; Carru, C.; Pintus, G. Resveratrol alters human endothelial cells redox state and causes mitochondrial-dependent cell death. Food Chem. Toxicol. 2015, 78, 10-16.
109. Zhang, H.; Zhang, J.; Ungvari, Z.; Zhang, C. Resveratrol improves endothelial function: Role of TNF and vascular oxidative stress. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 1164-1171.
110. Petit, M.; Guihot, A.L.; Grimaud, L.; Vessieres, E.; Toutain, B.; Menet, M.C.; Nivet-Antoine, V.; Arnal, J.F.; Loufrani, L.; Procaccio, V. et al. Resveratrol improved flow-mediated outward arterial remodeling in ovariectomized rats with hypertrophic effect at high dose. PLoS ONE 2016, 11, e0146148.
111. Hu, M.; Liu, B. Resveratrol via activation of LKB1-AMPK signaling suppresses oxidative stress to prevent endothelial dysfunction in diabetic mice. Clin. Exp. Hypertens. 2016, 5, 1-7.
112. Yan, C.; Xu, W.; Huang, Y.; Li, M.; Shen, Y.; You, H.; Liang, X. HRD1-mediated IGF-1R ubiquitination contributes to renal protection of resveratrol in db/db mice. Mol. Endocrinol. 2016.
113. Zhou, Y.; Chen, K.; He, L.; Xia, Y.; Dai, W.; Wang, F.; Li, J.; Li, S.; Liu, T.; Zheng, Y. et al. The Protective effect of resveratrol on concanavalin-A-induced acute hepatic injury in mice. Gastroenterol. Res. Pract. 2015, 2015, 506390.
114. Palsamy, P.; Subramanian, S. Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic β-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. J. Cell. Physiol. 2010, 224, 423-432.
115. Breen, D.M.; Sanli, T.; Giacca, A.; Tsiani, E. Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. Biochem. Biophys. Res. Commun. 2008, 374, 117-122.
116. Borriello, A.; Cucciolla, V.; della Ragione, F.; Galletti, P. Dietary polyphenols: Focus on resveratrol, a promising agent in the prevention of cardiovascular diseases and control of glucose homeostasis. Nutr. Metab. Cardiovasc. Dis. 2010, 20, 618-625.
117. Patel, M.I.; Gupta, A.; Dey, C.S. Potentiation of neuronal insulin signaling and glucose uptake by resveratrol: The involvement of AMPK. Pharmacol. Rep. 2011, 63, 1162-1168.
118. Gomez-Zorita, S.; Tréguer, K.; Mercader, J.; Carpéné, C. Resveratrol directly affects in vitro lipolysis and glucose transport in human fat cells. J. Physiol. Biochem. 2013, 69, 585-593.
119. Szkudelski, T.; Szkudelska, K. Resveratrol and diabetes: From animal to human studies. Biochim. Biophys. Acta 2015, 1852, 1145-1154.
120. Sun, C.; Zhang, F.; Ge, X.; Yan, T.; Chen, X.; Shi, X.; Zhai, Q. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 2007, 6, 307-319.
121. Deng, J.Y.; Hsieh, P.S.; Huang, J.P.; Lu, L.S.; Hung, L.M. Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and-independent pathways. Diabetes 2008, 57, 1814-1823.
122. Wang, Q.; Sun, X.; Li, X.; Dong, X.; Li, P.; Zhao, L. Resveratrol attenuates intermittent hypoxia-induced insulin resistance in rats: Involvement of Sirtuin 1 and the phosphatidylinositol-4,5-bisphosphate 3-kinase/AKT pathway. Mol. Med. Rep. 2015, 11, 151-158.
123. Bagul, P.K.; Deepthi, N.; Sultana, R.; Banerjee, S.K. Resveratrol ameliorates cardiac oxidative stress in diabetes through deacetylation of NFB-p65 and histone 3. J. Nutr. Biochem. 2015, 26, 1298-1307.
124. Diaz-Gerevini, G.T.; Repossi, G.; Dain, A.; Tarres, M.C.; Das, U.N.; Eynard, A.R. Beneficial action of resveratrol: How and why? Nutrition 2016, 32, 174-178.
125. Granados-Soto, V. Pleiotropic effects of resveratrol. Drug News Perspect. 2003, 16, 299-307.
126. Rodrigo, R.; Miranda, A.; Vergara, L. Modulation of endogenous antioxidant system by wine polyphenols in human disease. Clin. Chim. Acta 2011, 412, 410-424.
127. Kakoti, B.B.; Hernandez-Ontiveros, D.G.; Kataki, M.S.; Shah, K.; Pathak, Y.; Panguluri, S.K. Resveratrol and Omega-3 Fatty Acid: Its Implications in Cardiovascular Diseases. Front. Cardiovasc. Med. 2015, 11, 38.
128. Xia, N.; Förstermann, U.; Li, H. Resveratrol and endothelial nitric oxide. Molecules 2014, 19, 16102-16121.
129. Neves, A.R.; Nunes, C.; Amenitsch, H.; Reis, S. Effects of resveratrol on the structure and fluidity of lipid bilayers: A membrane biophysical study. Soft Matter 2016, 12, 2118-2126.
130. Marques, F.Z.; Markus, M.A.; Morris, B.J. Resveratrol: Cellular actions of a potent natural chemical that confers a diversity of health benefits. Int. J. Biochem. Cell Biol. 2009, 41, 2125-2128.
131. Cho, S.J.; Jung, U.J.; Choi, M.S. Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice. Br. J. Nutr. 2012, 108, 2166-2175.
132. Poulsen, M.M.; Vestergaard, P.F.; Clasen, B.F.; Radko, Y.; Christensen, L.P.; Stødkilde-Jørgensen, H.; Møller, N.; Jessen, N.; Pedersen, S.B.; Jørgensen, J.O. High-dose resveratrol supplementation in obese men: An investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013, 62, 1186-1195.
133. Walle, T.; Hsieh, F.; DeLegge, M.H.; Oatis, J.E., Jr.; Walle, U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32, 1377-1382.
134. la Porte, C.; Voduc, N.; Zhang, G.; Seguin, I.; Tardiff, D.; Singhal, N.; Cameron, D.W. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin. Pharmacokinet. 2010, 49, 449-454.
135. Kapetanovic, I.M.; Muzzio, M.; Huang, Z.; Thompson, T.N.; McCormick, D.L. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother. Pharmacol. 2011, 68, 593-601.
136. Malhotra, A.; Bath, S.; Elbarbry, F. An organ system approach to explore the antioxidative, anti-inflammatory, and cytoprotective actions of resveratrol. Oxid. Med. Cell. Longev. 2015, 2015, 803971.
137. Thazhath, S.S.; Wu, T.; Bound, M.J.; Checklin, H.L.; Standfield, S.; Jones, K.L.; Horowitz, M.; Rayner, C.K. Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: A randomized controlled trial. Am. J. Clin. Nutr. 2016, 103, 66-70.
138. Goh, K.P.; Lee, H.Y.; Lau, D.P.; Supaat, W.; Chan, Y.H.; Koh, A.F. Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. Int. J. Sport Nutr. Exerc. Metab. 2014, 24, 2-13.
139. Dash, S.; Xiao, C.; Morgantini, C.; Szeto, L.; Lewis, G.F. High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 2895-2901.
140. Tuorkey, M.J.; El-Desouki, N.I.; Kamel, R.A. Cytoprotective effect of silymarin against diabetes-induced cardiomyocyte apoptosis in diabetic rats. Biomed. Environ. Sci. 2015, 28, 36-43.
141. Lee, D.Y.; Liu, Y. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, Isolated from Silybum marianum (milk thistle). J. Nat. Prod. 2003, 66, 1171-1174.
142. Anthony, K.P.; Saleh, M.A. Free radical scavenging and antioxidant activities of silymarin components. Antioxidants 2013, 2, 398-407.
143. Kazazis, C.E.; Evangelopoulos, A.A.; Kollas, A.; Vallianou, N.G. The therapeutic potential of milk thistle in diabetes. Rev. Diabet. Stud. 2014, 11, 167-174.
144. Wu, C.H.; Huang, S.M.; Yen, G.C. Silymarin: A novel antioxidant with antiglycation and antiinflammatory properties in vitro and in vivo. Antioxid. Redox Signal. 2011, 14, 353-366.
145. Shin, S.; Lee, J.A.; Kim, M.; Kum, H.; Jung, E.; Park, D. Anti-glycation activities of phenolic constituents from Silybum marianum (Milk Thistle) flower in vitro and on human explants. Molecules 2015, 20, 3549-3564.
146. Sheela, N.; Jose, M.A.; Sathyamurthy, D.; Kumar, B.N. Effect of silymarin on streptozotocin-nicotinamide-induced type 2 diabetic nephropathy in rats. Iran J. Kidney Dis. 2013, 7, 117-123.
147. Khazim, K.; Gorin, Y.; Cavaglieri, R.C.; Abboud, H.E.; Fanti, P. The antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo. Am. J. Physiol. Ren. Physiol. 2013, 305, F691-F700.
148. Vessal, G.; Akmali, M.; Najafi, P.; Moein, M.R.; Sagheb, M.M. Silymarin and milk thistle extract may prevent the progression of diabetic nephropathy in streptozotocin-induced diabetic rats. Ren. Fail. 2010, 32, 733-739.
149. Baluchnejadmojarad, T.; Roghani, M.; Khastehkhodaie, Z. Chronic treatment of silymarin improves hyperalgesia and motor nerve conduction velocity in diabetic neuropathic rat. Phytother. Res. 2010, 24, 1120-1125.
150. Marrazzo, G.; Bosco, P.; la Delia, F.; Scapagnini, G.; di Giacomo, C.; Malaguarnera, M.; Galvano, F.; Nicolosi, A.; Li Volti, G. Neuroprotective effect of silibinin in diabetic mice. Neurosci. Lett. 2011, 504, 252-256.
151. Borah, A.; Paul, R.; Choudhury, S.; Choudhury, A.; Bhuyan, B.; Das Talukdar, A.; Dutta Choudhury, M.; Mohanakumar, K.P. Neuroprotective potential of silymarin against CNS disorders: Insight into the pathways and molecular mechanisms of action. CNS Neurosci. Ther. 2013, 19, 847-853.
152. Velussi, M.; Cernigoi, A.M.; De Monte, A.; Dapas, F.; Caffau, C.; Zilli, M. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J. Hepatol. 1997, 26, 871-879.
153. Huseini, H.F.; Larijani, B.; Heshmat, R.; Fakhrzadeh, H.; Radjabipour, B.; Toliat, T.; Raza, M. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: A randomized, double-blind, placebo-controlled, clinical trial. Phytother. Res. 2006, 20, 1036-1039.
154. Hussain, S.A. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. J. Med. Food 2007, 10, 543-547.
155. Ebrahimpour Koujan, S.; Gargari, B.P.; Mobasseri, M.; Valizadeh, H.; Asghari-Jafarabadi, M. Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: A randomized, triple-blind, placebo-controlled clinical trial. Phytomedicine 2015, 22, 290-296.
156. Fallahzadeh, M.K.; Dormanesh, B.; Sagheb, M.M.; Roozbeh, J.; Vessal, G.; Pakfetrat, M.; Daneshbod, Y.; Kamali-Sarvestani, E.; Lankarani, K.B. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: A randomized, double-blind, placebo-controlled trial. Am. J. Kidney Dis. 2012, 60, 896-903.
157. Gueutin, V.; Gauthier, M.; Cazenave, M.; Izzedine, H. Diabetic nephropathy: Emerging treatments. Nephrol. Ther. 2014, 10, 210-215.
158. Magliulo, E.; Gagliardi, B.; Fiori, G.P. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres. Med. Klin. 1978, 73, 1060-1065.
159. Hollman, P.C.; de Vries, J.H.; van Leeuwen, S.D.; Mengelers, M.J.; Katan, M.B. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am. J. Clin. Nutr. 1995, 62, 1276-1282.
160. Boocock, D.J.; Faust, G.E.; Patel, K.R.; Schinas, A.M.; Brown, V.A.; Ducharme, M.P.; Booth, T.D.; Crowell, J.A.; Perloff, M.; Gescher, A.J. et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomark. Prev. 2007, 16, 1246-1252.
161. Hawke, R.L.; Schrieber, S.J.; Soule, T.A.; Wen, Z.; Smith, P.C.; Reddy, K.R.; Wahed, A.S.; Belle, S.H.; Afdhal, N.H.; Navarro, V.J. et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J. Clin. Pharmacol. 2010, 50, 434-449.
162. Lecomte, J. Pharmacologic properties of silybin and silymarin. Rev. Med. Liege 1975, 30, 110-114.
163. O'Connor, L.M.; Lentjes, M.A.; Luben, R.N.; Khaw, K.T.; Wareham, N.J.; Forouhi, N.G. Dietary dairy product intake and incident type 2 diabetes: A prospective study using dietary data from a 7-day food diary. Diabetologia 2014, 57, 909-917.
164. Pasin, G.; Comerford, K.B. Dairy foods and dairy proteins in the management of type 2 diabetes: A systematic review of the clinical evidence. Adv. Nutr. 2015, 6, 245-259.
165. Astrup, A. Yogurt and dairy product consumption to prevent cardiometabolic diseases: Epidemiologic and experimental studies. Am. J. Clin. Nutr. 2014, 99, 1235S-1242S.
166. Ejtahed, H.S.; Soroush, A.R.; Angoorani, P.; Larijani, B.; Hasani-Ranjbar, S. Gut microbiota as a target in the pathogenesis of metabolic disorders: A new approach to novel therapeutic agents. Horm. Metab. Res. 2016, 48, 349-358.
167. Aune, D.; Norat, T.; Romundstad, P.; Vatten, L.J. Dairy products and the risk of type 2 diabetes: A systematic review and dose-response meta-analysis of cohort studies. Am. J. Clin. Nutr. 2013, 98, 1066-1083.
168. Hadisaputro, S.; Djokomoeljanto, R.R.; Judiono Soesatyo, M.H. The effects of oral plain kefir supplementation on proinflammatory cytokine properties of the hyperglycemia Wistar rats induced by streptozotocin. Acta Med. Indones. 2012, 44, 100-104.
169. Bourrie, B.C.; Willing, B.P.; Cotter, P.D. The microbiota and health promoting characteristics of the fermented beverage kefir. Front. Microbiol. 2016, 7, 647.
170. Magalhães, K.T.; de Melo Pereira, G.V.; Campos, C.R.; Dragone, G.; Schwan, R.F. Brazilian kefir: Structure, microbial communities and chemical composition. Braz. J. Microbiol. 2011, 42, 693-702.
171. De Oliveira Leite, A.M.; Miguel, M.A.; Peixoto, R.S.; Rosado, A.S.; Silva, J.T.; Paschoalin, V.M. Microbiological, technological and therapeutic properties of kefir: A natural probiotic beverage. Braz. J. Microbiol. 2013, 44, 341-349.
172. Friques, A.G.; Arpini, C.M.; Kalil, I.C.; Gava, A.L.; Leal, M.A.; Porto, M.L.; Nogueira, B.V.; Dias, A.T.; Andrade, T.U.; Pereira, T.M. et al. Chronic administration of the probiotic kefir improves the endothelial function in spontaneously hypertensive rats. J. Transl. Med. 2015, 13, 390.
173. Zhou, J.; Liu, X.; Jiang, H.; Dong, M. Analysis of the microflora in Tibetan kefir grains using denaturing gradient gel electrophoresis. Food Microbiol. 2009, 26, 770-775.
174. Leite, A.M.; Mayo, B.; Rachid, C.T.; Peixoto, R.S.; Silva, J.T.; Paschoalin, V.M.; Delgado, S. Assessment of the microbial diversity of Brazilian kefir grains by PCR-DGGE and pyrosequencing analysis. Food Microbiol. 2012, 31, 215-221.
175. Hamet, M.F.; Londero, A.; Medrano, M.; Vercammen, E.; van Hoorde, K.; Garrote, G.L.; Huys, G.; Vandamme, P.; Abraham, A.G. Application of culture-dependent and culture-independent methods for the identification of Lactobacillus kefiranofaciens in microbial consortia present in kefir grains. Food Microbiol. 2013, 36, 327-334.
176. Marsh, A.J.; O’Sullivan, O.; Hill, C.; Ross, R.P.; Cotter, P.D. Sequencing-based analysis of the bacterial and fungal composition of kefir grains and milks from multiple sources. PLoS ONE 2013, 8, e69371.
177. Gonçalves, N.; Gomes-Ferreira, C.; Moura, C.; Roncon-Albuquerque, R., Jr.; Leite-Moreira, A.F.; Falcão-Pires, I. Worse cardiac remodeling in response to pressure overload in type 2 diabetes mellitus. Int. J. Cardiol. 2016, 217, 195-204.
178. Punaro, G.R.; Maciel, F.R.; Rodrigues, A.M.; Rogero, M.M.; Bogsan, C.S.; Oliveira, M.N.; Ihara, S.S.; Araujo, S.R.; Sanches, T.R.; Andrade, L.C. et al. Kefir administration reduced progression of renal injury in STZ-diabetic rats by lowering oxidative stress. Nitric Oxide 2014, 37, 53-60.
179. Yadav, H.; Jain, S.; Sinha, P.R. Oral administration of dahi containing probiotic Lactobacillus acidophilus and Lactobacillus casei delayed the progression of streptozotocin-induced diabetes in rats. J. Dairy Res. 2008, 75, 189-195.
180. Maeda, H.; Zhu, X.; Omura, K.; Suzuki, S.; Kitamura, S. Effects of an exopolysaccharide (kefiran) on lipids, blood pressure, blood glucose, and constipation. Biofactors 2004, 22, 197-200.
181. Maeda, H.; Zhu, X.; Suzuki, S.; Suzuki, K.; Kitamura, S. Structural characterization and biological activities of an exopolysaccharide kefiran produced by Lactobacillus kefiranofaciens WT-2B(T). J. Agric. Food Chem. 2004, 52, 5533-5338.
182. Teruya, K.; Yamashita, M.; Tominaga, R.; Nagira, T.; Shim, S.Y.; Katakura, Y.; Tokumaru, S.; Tokumaru, K.; Barnes, D.; Shirahata, S. Fermented milk, Kefram-Kefir enhances glucose uptake into insulin-responsive muscle cells. Cytotechnology 2002, 40, 107-116.
183. Yadav, H.; Jain, S.; Sinha, P.R. Effect of Dahi containing Lactococcus lactis on the progression of diabetes induced by a high-fructose diet in rats. Biosci. Biotechnol. Biochem. 2006, 70, 1255-1258.
184. Asemi, Z.; Zare, Z.; Shakeri, H.; Sabihi, S.S.; Esmaillzadeh, A. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Ann. Nutr. Metab. 2013.
185. Rudich, A.; Kozlovsky, N.; Potashnik, R.; Bashan, N. Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes. Am. J. Physiol. 1997, 272, E935-E940.
186. Rudich, A.; Tirosh, A.; Potashnik, R.; Hemi, R.; Kanety, H.; Bashan, N. Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes 1998, 47, 1562-1569.
187. Baynes, J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 1991, 40, 405-412.
188. Wolff, S.P.; Jiang, Z.Y.; Hunt, J.V. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic. Biol. Med. 1991, 10, 339-352.
189. Klippel, B.F.; Duemke, L.B.; Leal, M.A.; Friques, A.G.F.; Dantas, E.M.; Dalvi, R.F.; Gava, A.L.; Pereira, T.M.C.; Andrade, T.U.; Meyrelles, S.S. et al. Effects of kefir on the cardiac autonomic tones and baroreflex sensitivity in spontaneously hypertensive rats. Front. Physiol. 2016, 7, 211.
190. Liu, Y.; Liu, S.X.; Zheng, F.; Cai, Y.; Xie, K.L.; Zhang, W.L. Cardiovascular autonomic neuropathy in patients with type 2 diabetes. J. Diabetes Investig. 2015.
191. Li, X.; Jiang, Y.H.; Jiang, P.; Lin, H.Q.; Yang, J.L.; Ma, D.F.; Wang, X.; Yang, C.H. Analysis of heart rate variability and cardiac autonomic nerve remodeling in streptozotocin-induced diabetic rats. Exp. Clin. Endocrinol. Diabetes 2015, 123, 272-281.
192. Firouzi, S.; Majid, H.A.; Ismail, A.; Kamaruddin, N.A.; Barakatun-Nisak, M.Y. Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: A randomized controlled trial. Eur. J. Nutr. 2016.
193. Ostadrahimi, A.; Taghizadeh, A.; Mobasseri, M.; Farrin, N.; Payahoo, L.; Beyramalipoor Gheshlaghi, Z.; Vahedjabbari, M. Effect of probiotic fermented milk (kefir) on glycemic control and lipid profile in type 2 diabetic patients: A randomized double-blind placebo-controlled clinical trial. Iran J. Public Health 2015, 44, 228-237.
194. Hulston, C.J.; Churnside, A.A.; Venables, M.C. Probiotic supplementation prevents high-fat, overfeeding-induced insulin resistance in human subjects. Br. J. Nutr. 2015, 113, 596-602.
195. Tonucci, L.B.; Olbrich Dos Santos, K.M.; Licursi de Oliveira, L.; Rocha Ribeiro, S.M.; Duarte Martino, H.S. Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Clin. Nutr. 2015.
196. Manaer, T.; Yu, L.; Zhang, Y.; Xiao, X.J.; Nabi, X.H. Anti-diabetic effects of shubat in type 2 diabetic rats induced by combination of high-glucose-fat diet and low-dose streptozotocin. J. Ethnopharmacol. 2015, 169, 269-274.
197. Kuschnerus, K.; Landmesser, U.; Kränkel, N. Vascular repair strategies in type 2 diabetes: Novel insights. Cardiovasc. Diagn. Ther. 2015, 5, 374-386.
198. Ramirez, C.E.; Nian, H.; Yu, C.; Gamboa, J.L.; Luther, J.M.; Brown, N.J.; Shibao, C.A. Treatment with sildenafil improves insulin sensitivity in prediabetes: A randomized, controlled trial. J. Clin. Endocrinol. Metab. 2015, 100, 4533-4540.
199. Gromada, J.; Høy, M.; Renström, E.; Bokvist, K.; Eliasson, L.; Göpel, S.; Rorsman, P. CaM kinase II-dependent mobilization of secretory granules underlies acetylcholine-induced stimulation of exocytosis in mouse pancreatic B-cells. J. Physiol. 1999, 518, 745-759.
200. Fu, Z.; Gilbert, E.R.; Liu, D. Regulation of insulin synthesis and secretion and pancreatic β-cell dysfunction in diabetes. Curr. Diabetes Rev. 2013, 9, 25-53.
201. Nyström, T.; Ortsäter, H.; Huang, Z.; Zhang, F.; Larsen, F.J.; Weitzberg, E.; Lundberg, J.O.; Sjöholm, Å. Inorganic nitrite stimulates pancreatic islet blood flow and insulin secretion. Free Radic. Biol. Med. 2012, 53, 1017-1023.
202. Méndez-del Villar, M.; González-Ortiz, M.; Martínez-Abundis, E.; Pérez-Rubio, K.G.; Lizárraga-Valdez, R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab. Syndr. Relat. Disord. 2014, 12, 497-501.
203. Otunola, G.A.; Oloyede, O.B.; Oladiji, A.T.; Afolayan, A.J. Selected spices and their combination modulate hypercholesterolemia-induced oxidative stress in experimental rats. Biol. Res. 2014, 47, 5.
204. Bergandi, L.; Silvagno, F.; Russo, I.; Riganti, C.; Anfossi, G.; Aldieri, E.; Ghigo, D.; Trovati, M.; Bosia, A. Insulin stimulates glucose transport via nitric oxide/cyclic GMP pathway in human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 2215-2221.
205. Tanaka, T.; Nakatani, K.; Morioka, K.; Urakawa, H.; Maruyama, N.; Kitagawa, N.; Katsuki, A.; Araki-Sasaki, R.; Hori, Y.; Gabazza, E.C. et al. Nitric oxide stimulates glucose transport through insulin-independent GLUT4 translocation in 3T3-L1 adipocytes. Eur. J. Endocrinol. 2003, 149, 61-67.
206. Lira, V.A.; Soltow, Q.A.; Long, J.H.; Betters, J.L.; Sellman, J.E.; Criswell, D.S. Nitric oxide increases GLUT4 expression and regulates AMPK signaling in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 2007, 293, E1062-E1068.
207. Furchgott, R.F.; Zawadzki, J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288, 373-376.
208. Ignarro, L.J. Nitric oxide: A unique endogenous signaling molecule in vascular biology. Biosci. Rep. 1999, 19, 51-71.
209. Vasquez, E.C.; Gava, A.L.; Graceli, J.B.; Balarini, C.M.; Campagnaro, B.P.; Pereira, T.M.; Meyrelles, S.S. Novel therapeutic targets for phosphodiesterase 5 inhibitors: Current state-of-the-art on systemic arterial hypertension and atherosclerosis. Curr. Pharm. Biotechnol. 2016, 17, 347-364.
210. Behr-Roussel, D.; Oudot, A.; Caisey, S.; Coz, O.L.; Gorny, D.; Bernabé, J.; Wayman, C.; Alexandre, L.; Giuliano, F.A. Daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance. Eur. Urol. 2008, 53, 1272-1280.
211. Maiorino, M.I.; Bellastella, G.; Esposito, K. Diabetes and sexual dysfunction: Current perspectives. Diabetes Metab. Syndr. Obes. 2014, 7, 95-105.
212. Leal, M.A.; Balarini, C.M.; Dias, A.T.; Porto, M.L.; Gava, A.L.; Pereira, T.M.; Meyrelles, S.S.; Vasquez, E.C. Mechanisms of enhanced vasoconstriction in the mouse model of atherosclerosis: The beneficial effects of sildenafil. Curr. Pharm. Biotechnol. 2015, 16, 517-530.
213. Bai, Y.; An, R. Resveratrol and sildenafil synergistically improve diabetes-associated erectile dysfunction in streptozotocin-induced diabetic rats. Life Sci. 2015, 135, 43-48.
214. Dalaklioglu, S.; Bayram, Z.; Tasatargil, A.; Ozdem, S. Resveratrol reverses diabetes-related decrement in sildenafil-induced relaxation of corpus cavernosum in aged rats. Aging Clin. Exp. Res. 2016.
215. Bivalacqua, T.J.; Sussan, T.E.; Gebska, M.A.; Strong, T.D.; Berkowitz, D.E.; Biswal, S.; Burnett, A.L.; Champion, H.C. Sildenafil inhibits superoxide formation and prevents endothelial dysfunction in a mouse model of secondhand smoke induced erectile dysfunction. J. Urol. 2009, 181, 899-906.
216. Balarini, C.M.; Leal, M.A.; Gomes, I.B.; Pereira, T.M.; Gava, A.L.; Meyrelles, S.S.; Vasquez, E.C. Sildenafil restores endothelial function in the apolipoprotein E knockout mouse. J. Transl. Med. 2013, 11, 3.
217. Dias, A.T.; Cintra, A.S.; Frossard, J.C.; Palomino, Z.; Casarini, D.E.; Gomes, I.B.; Balarini, C.M.; Gava, A.L.; Campagnaro, B.P.; Pereira, T.M. et al. Inhibition of phosphodiesterase 5 restores endothelial function in renovascular hypertension. J. Transl. Med. 2014, 12, 250.
218. Fahning, B.M.; Dias, A.T.; Oliveira, J.P.; Gava, A.L.; Porto, M.L.; Gomes, I.B.; Nogueira, B.V.; Campagnaro, B.P.; Pereira, T.M.; Vasquez, E.C. et al. Sildenafil improves vascular endothelial structure and function in renovascular hypertension. Curr. Pharm. Biotechnol. 2015, 16, 823-831.
219. de Almeida, L.S.; Barboza, J.R.; Freitas, F.P.; Porto, M.L.; Vasquez, E.C.; Meyrelles, S.S.; Gava, A.L.; Pereira, T.M. Sildenafil prevents renal dysfunction in contrast media-induced nephropathy inWistar rats. Hum. Exp. Toxicol. 2016.
220. Aversa, A.; Vitale, C.; Volterrani, M.; Fabbri, A.; Spera, G.; Fini, M.; Rosano, G.M. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med. 2008, 25, 37-44.
221. Kondoh, N.; Higuchi, Y.; Maruyama, T.; Nojima, M.; Yamamoto, S.; Shima, H. Salvage therapy trial for erectile dysfunction using phosphodiesterase type 5 inhibitors and vitamin E: Preliminary report. Aging Male 2008, 11, 167-170.
222. Mandosi, E.; Giannetta, E.; Filardi, T.; Lococo, M.; Bertolini, C.; Fallarino, M.; Gianfrilli, D.; Venneri, M.A.; Lenti, L.; Lenzi, A. et al. Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes. Expert Opin. Ther. Targets 2015, 19, 1617-1622.
223. Balhara, Y.P.; Sarkar, S.; Gupta, R. Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Indian J. Endocrinol. Metab. 2015, 19, 451-461.
224. Das, A.; Durrant, D.; Salloum, F.N.; Xi, L.; Kukreja, R.C. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol. Ther. 2015, 147, 12-21.
225. Mammi, C.; Pastore, D.; Lombardo, M.F.; Ferrelli, F.; Caprio, M.; Consoli, C.; Tesauro, M.; Gatta, L.; Fini, M.; Federici, M. et al. Sildenafil reduces insulin-resistance in human endothelial cells. PLoS ONE 2011, 6, e14542.
226. Ayala, J.E.; Bracy, D.P.; Julien, B.M.; Rottman, J.N.; Fueger, P.T.; Wasserman, D.H. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 2007, 56, 1025-1033.
227. Varma, A.; Das, A.; Hoke, N.N.; Durrant, D.E.; Salloum, F.N.; Kukreja, R.C. Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice. PLoS ONE 2012, 7, e45243.
228. Koka, S.; Das, A.; Salloum, F.N.; Kukreja, R.C. Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice. Free Radic. Biol. Med. 2013, 60, 80-88.
229. Grover-Páez, F.; Villegas Rivera, G.; Guillén Ortíz, R. Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2007, 78, 136-140.
230. Chrysant, S.G.; Chrysant, G.S. The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension. J. Clin. Hypertens. 2012, 14, 644-649.